

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION

As at 30 June 2011

30 June

31 December

	30 June 2011 <i>HK\$'000</i> (Unaudited)	31 December 2010 <i>HK\$'000</i> (Audited)
Capital and reserves		
Share capital	16,306	15,511
Reserves	704,505	688,090

The Group has not early applied new or revised standards that have been issued but are not yet effective. The following new or revised standards have been issued after the date the consolidated financial statements for the year ended 31 December 2010 were authorised for issuance and are not yet effective:

HKFRS 10	Consolidated Financial Statements ²
HKFRS 11	Joint Arrangement ²
HKFRS 12	Disclosures of Interests in Other Entities ²
HKFRS 13	Fair Value Measurement ²
HKAS 1 (Revised)	Presentation of Financial Statements ¹
HKAS 19 (as revised in 2011)	Employee Benefits ²
HKAS 27 (as revised in 2011)	Separate Financial Statements ²
HKAS 28 (as revised in 2011)	Investments in Associates ²

4. TURNOVER AND SEGMENT INFORMATION

Turnover represents amount received and receivable from sales of pharmaceutical and food products net of returns, discounts allowed, sales related taxes and rental income during the period.

The following is an analysis of the Group's revenue and results by reportable and operating segments for the period under review:

Six months ended 30 June 2011

Pharmaceutical and food <i>HK\$'000</i>	Property investment <i>HK\$'000</i>	Total <i>HK\$'000(Unaudies) U</i>
--	--	--

The following is an analysis of the Group's assets by reportable and operating segments:

	30 June 2011 <i>HK\$'000</i> (Unaudited)	31 December 2010 <i>HK\$'000</i> (Audited)
Pharmaceutical and food	360,796	435,762
Property investment	369,617	345,394

The Hong Kong Profits Tax amounting to HK\$7,791,000 of a subsidiary of the Company in respect of the

7. DISPOSAL OF SUBSIDIARIES

On 15 April 2011, the Group entered into sale agreements to dispose of its 100% equity interest in a

(b) Capital commitments for properties under development

	30 June 2011 <i>HK\$'000</i> (Unaudited)	31 December 2010 <i>HK\$'000</i> (Audited)
Contracted but not provided for	4,088	230
Authorised but not contracted for	770,225	759,439

Sichuan Hengtai Pharmaceutical Company Limited

Sichuan Hengtai is the major sales arm of the Group. During the period under review, major sales products included: “Osteoform Calcium Food”, Madaus products, “Osteoform Vitamins with minerals dispersible tablet”, “Taurolite[®]” and “Vita77ast” etc.d

Exposure to foreign exchange risk and Currency policy

During the reporting period and the corresponding period, the sales receipts of the Group were mainly denominated in RMB. Purchases were denominated as to approximately 30% in RMB (2010: 32%), approximately 37% in USD (2010: 42%) and approximately 33% in EURO (2010: 26%). Operating expenditures including selling and distribution expenses and administrative expenses were denominated as to approximately 73% in RMB (2010: 76%),

Finance costs: Although the Group had bank borrowings in the year 2011, interest expenses amounted to HK\$2 million have been capitalized into property under development. Therefore,

Dividend

